Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: Comparison with ketoconazole

European Journal of Clinical Pharmacology

Volumn 56, Issue 3, 2000, Pages 259-261

  Von Moltke, L L ^a,b   Durol, A L B ^a,b   Duan, S X ^a,b   Greenblatt, D J ^a,b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Amprenavir; Human CYP3A; Ritonavir

Indexed keywords

AMPRENAVIR; CYTOCHROME P450 3A; KETOCONAZOLE; PROTEINASE INHIBITOR; RITONAVIR;

ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSFORMATION; ENZYME INHIBITOR INTERACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER MICROSOME; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; CARBAMATES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; HYDROXYLATION; KETOCONAZOLE; OXIDOREDUCTASES, N-DEMETHYLATING; RITONAVIR; SULFONAMIDES; TRIAZOLAM;

EID: 0033948964     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000125     Document Type: Article

References (19)

1. 1. Iribarne C, Berthou F, Carlhant D, Dreano Y, Picart D, Lohezic F, Riche C (1998) Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 26: 257-260
2. 2. Eagling VA, Back DJ, Barry MG (1997) Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44: 190-194
3. 3. Kumar GN, Rodrigues AD, Buko AM, Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277: 423-431
4. 4. Zalma A, von Moltke LL, Granda BW, Harmatz JS, Shader RI, Greenblatt DJ (2000) In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and viral protease inhibitors. Biol Psychiatry 47: 655-661
5. 5. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26: 552-561
6. 6. Inaba T, Fischer NE, Riddick DS, Stewart DJ, Hidaka T (1997) HIV protease inhibitors, saquinavir, indinavir and ritonavir: inhibition of CYP3A4-mediated metabolism of testosterone and benzoxazinorifamycin, KRM-1648, in human liver microsomes. Toxicol Lett 93: 215-219
7. 7. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, Shader RI (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38: 106-111
8. 8. Ouellet D, Hsu A, Granneman GR, Carlson G, Cavanaugh J, Guenther H, Leonard JM (1998) Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 64: 355-362
9. 9. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI (1999) Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 19: 293-296
10. 10. Hsu A, Granneman GR, Bertz RJ (1998) Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35: 275-291
11. 11. Barry M, Mulcahy F, Merry C, Gibbons S, Back D (1999) Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36: 289-304
12. 12. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol ALB, Daily JP, Graf JA, Mertzanis P, Hoffman JL, Shader RI (2000) Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther (in press)
13. 13. Sadler BM, Hanson CD, Chittick GE, Symonds WT, Roskell NS (1999) Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother 43: 1686-1692
14. 14. Decker CJ, Laitinen LM, Bridson GW, Raybuck SA, Tung RD, Chaturvedi PR (1998) Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 87: 803-807
15. 15. von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Shader RI (1998) Inhibition of triazolam hydroxylation by ketoconazole, itraconazole, hydroxyitraconazole and fluconazole in vitro. Pharm Pharmacol Commun 4: 443-445
16. 16. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276: 370-379
17. 17. von Moltke LL, Greenblatt DJ, Duan SX, Schmider J, Kudchadker L, Fogelman SM, Harmatz JS, Shader RI (1996) Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology (Berl) 128: 398-407
18. 18. Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol ALB, Mertzanis P, Duan SX, Wright CE, Shader RI (1998) Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 64: 278-285
19. 19. Silverman R (1992) Mechanism-based enzyme inactivators. Methods Enzymol 249: 241-282